Cardiol Therapeutics Files 6-K with News Release
Ticker: CRDL · Form: 6-K · Filed: Jun 13, 2024 · CIK: 1702123
| Field | Detail |
|---|---|
| Company | Cardiol Therapeutics INC. (CRDL) |
| Form Type | 6-K |
| Filed Date | Jun 13, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, news-release, regulatory
Related Tickers: CRDL
TL;DR
Cardiol Therapeutics (CRDL) filed a 6-K on 6/13/24, including a news release. Check for updates.
AI Summary
Cardiol Therapeutics Inc. filed a Form 6-K on June 13, 2024, reporting information for the month of June 2024. The filing includes a news release dated June 13, 2024, as Exhibit 99.1. The company is incorporated in Canada and its principal executive offices are located in Oakville, Ontario.
Why It Matters
This filing provides an update from Cardiol Therapeutics, potentially containing material news or developments relevant to investors.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to submit a news release, indicating no immediate significant financial or operational changes are being disclosed.
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — Filer of the 6-K report
- June 13, 2024 (date) — Date of the filing and news release
- Oakville, Ontario, Canada (location) — Location of principal executive offices
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report information for the month of June 2024, including a news release dated June 13, 2024, as Exhibit 99.1.
When was this Form 6-K filed?
This Form 6-K was filed on June 13, 2024.
Where are Cardiol Therapeutics Inc.'s principal executive offices located?
Cardiol Therapeutics Inc.'s principal executive offices are located at 602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5.
What exhibit is included with this filing?
Exhibit 99.1, a news release dated June 13, 2024, is included with this filing.
Does Cardiol Therapeutics Inc. file annual reports under Form 20-F or Form 40-F?
Cardiol Therapeutics Inc. indicates that it files annual reports under Form 20-F.
Filing Stats: 224 words · 1 min read · ~1 pages · Grade level 13.5 · Accepted 2024-06-13 07:59:31
Filing Documents
- form6k.htm (6-K) — 6KB
- exhibit99-1.htm (EX-99.1) — 14KB
- exhibit99-1xu001.jpg (GRAPHIC) — 7KB
- 0001062993-24-012565.txt ( ) — 31KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CARDIOL THERAPEUTICS INC. (Registrant) Date: June 13, 2024 By: /s/ Chris Waddick Chris Waddick Title: Chief Financial Officer